Returning to the pre-inflation shock level of $318 means that PODD stock will have to gain more than 100% from here.

Insulet's (PODD) international expansion efforts are aligned with its long-term growth profile.

Insulet's CEO stated today that new diabetes drugs could impact how quickly patients begin insulin therapy. However, the company doesn't expect any long-term impact on sales of its insulin pumps.

Insulin pumps maker Insulet Corp said on Thursday a new generation of diabetes drugs, known as GLP-1s, could delay the time that diabetes patients become dependent on insulin, sending its shares do...

The healthcare sector has underperformed this year, with the Health Care Select Sector SPDR (NYSEARCA: XLV ) down 1%. After a disappointing year-to-date performance, it's time to consider some top ...

The medical device specialist's CEO made a large purchase in its stock on Monday. The total outlay for the shares topped $1 million.

Insulet's (PODD) Omnipod 5 is available in the United States and the United Kingdom.

Insulet Corporation has seen a 30% drop in its shares despite solid Q2 earnings and strong commercial traction. The company aims to simplify the lives of people with diabetes and reduce the burden ...

Insulet's (PODD) Omnipod 5 gains market share in the second quarter within the diabetes technology market as the only FDA-approved fully disposable, pod-based automated insulin delivery system.

Insulet (PODD) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to loss of $0.06 per share a year ago.

The headline numbers for Insulet (PODD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estima...

Insulet Corp on Tuesday raised its annual revenue growth forecast and beat second-quarter profit and revenue estimates, on strong demand for its tubeless insulin pumps that are more convenient to u...